메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Helicobacter pylori infection causes peptic ulcer, gastric cancer and gastric mucosa-associated lymphoid-tissue lymphoma. H. pylori eradication has played a major role in the prevention and treatment of these diseases. The guidelines for the diagnosis and treatment of H. pylori infection in Korea recommends standard triple therapy consisting of proton pump inhibitor, clarithromycin and amoxicillin as the first line eradication therapy and quadruple therapy including bismuth in case of clarithromycin-resistant H. pylori infection. However, the eradication rate of conventional first line therapy of H. pylori infection has been decreasing during last decade. Recently the eradication rate of standard triple therapy in Korea is reported to be lower than 80% and sometimes even lower than 70% (intention-to-treat). Therefore, the need for the new first line eradication regimen has been rising. Sequential therapy, concomitant therapy and tailored therapy have been introduced as new options for the first line therapy. However, they have yet to be proven as the standard therapy and need further study.

목차

등록된 정보가 없습니다.

참고문헌 (39)

참고문헌 신청

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0